The value of real-world evidence in Canadian drug commercialization

The growing need for Canadian biopharma and biosimilar companies to demonstrate product value to health technology agencies (HTAs) and payers to gain and maintain access is driving changes to commercialization strategies along the product lifecycle. As decision-making among these stakeholders is increasingly focused on value and outcome measures, there is a need for additional evidence generation beyond traditional randomized clinical trials (RCTs) during the pre-launch phase.

Across the product lifecycle Canadian biopharma companies have the unique opportunity to leverage their investment in Patient-Support Programs (PSPs) as a critical tool for shaping market access strategies, commercialization goals and improving patient outcomes. PSPs provide a rich data set that can be supplemented and leveraged as a strategic imperative. Discover how InnomarConsulting and RWE can enhance your portfolio from pre-launch to maturity. Read the full article and contact us to start your RWE journey today.